KDR and hepatocellular carcinoma: Zhu et al. performed molecular analyses on tumor samples from 358 patients with HCC enrolled in the phase Ib and in the IMbrave150 phase III studies, demonstrating that improved outcomes from the combination versus atezolizumab alone were associated with high expression of VEGFR2, Tregs and myeloid inflammation signatures [119].